These interactions, such as the associations we have described here, may help in the selection of phenotypic biomarkers, and in the selection of new therapeutic agents, such as FXR agonists, which could benefit a targeted group of patients with BAD and NAFLD or NASH. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.